Get Support

Search global stocks & ETFs...Ctrl K

Learn Mode

GILD - Gilead Sciences, Inc

141

$133.37

-$1.57 (-1.163%)

5/13/26, 1:42 PM

3.71/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

GILD

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$167.54B

Industry

Biotechnology

EPS (TTM)

$7.35

P/E (TTM)

18.18

Div & Yield

$3.28 (2.46%)

FCF Payout Ratio

41.13%

P/S (TTM)

5.63

P/B

7.12

Diluted Shares

1.25B

Ex-Dividend

2026-06-15

Next Earnings

08-05

Forward P/E

14.61

Payout Ratio

44.71%

P/FCF (TTM)

16.72

FCF Yield

5.98%

Earnings Yield

5.50%

52 Week Range

Score Card

Explore Scores Tab

3.71

Good

Gilead Sciences, Inc has grown revenue at 3.48% over the past year, which suggests sales are increasing. Also, it has a free cash flow margin of 33.69%, which suggests the company is very profitable.

Valuation Model

Key Score

2.00

Bad

Management

4.00

Good

Growth

3.00

Average

Profitability

3.00

Average

Fin. Health

3.00

Average

Dividends

1.00

Very Bad

Analyst

1.00

Very Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

4 new filings were in the last 7 days

Filter Form Types

Form 13F-HR

Unknown Form Type

Filed on 2026-05-08 17:00:48

Form S-8

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Filed on 2026-05-07 17:13:48

Form 10-Q

General form for quarterly financial reports under Section 13 or 15(d)

Filed on 2026-05-07 17:12:20

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-07 16:03:01

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-04 16:40:28

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-04 16:36:45

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-04 16:31:49

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-04 16:28:34

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-04 16:25:01

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-04 16:22:58

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-04 16:20:56

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-04 16:19:20

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$189.00

41.7%

Avg:

$162.01

21.5%

Low:

$124.23

-6.9%

(% change is relative to the current stock price: $133.37)

Analyst Recommendations

Go to Analyst Tab

4.08

Good

28%

Strong Buy (11)

51%

Buy (20)

21%

Hold (8)

0%

Sell (0)

0%

Strong Sell (0)

About

Website
https://www.gilead.com
Address
333 Lakeside Dr, Foster City CALIFORNIA, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=882095

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,000 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Livdelzi/Lyvdelzi, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada for PrEP, and others. The company also sells and distributes authorized generic versions of Epclusa and Harvoni in the United States through its subsidiary, Asegua Therapeutics LLC. The company has control on anitocabtagene autoleucel (anito cel), an investigational BCMA-directed CAR T cell therapy for multiple myeloma. The company operates in over 35 countries worldwide.

IPO Date

1992-01-22

Industry

Biotechnology

Total Employees

17,000

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences